ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

ClinicalTrials.gov ID: NCT07209111

Public ClinicalTrials.gov record NCT07209111. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 12:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)

Study identification

NCT ID
NCT07209111
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
150 participants

Conditions and interventions

Interventions

  • Calderasib Drug
  • Cetuximab Biological

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 3, 2025
Primary completion
Apr 8, 2032
Completion
Apr 8, 2032
Last update posted
May 3, 2026

2025 – 2032

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
Greater Baltimore Medical Center ( Site 1104) Baltimore Maryland 21204 Recruiting
START Midwest ( Site 1103) Grand Rapids Michigan 49546 Recruiting
Comprehensive Cancer Centers of Nevada ( Site 1109) Las Vegas Nevada 89169 Recruiting
Rutgers Cancer Institute of New Jersey ( Site 1100) New Brunswick New Jersey 08903 Recruiting
START Mountain Region ( Site 1106) West Valley City Utah 84119 Recruiting
Virginia Cancer Specialists ( Site 1102) Fairfax Virginia 22031 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07209111, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 3, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07209111 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →